Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 138.9
-3.12 %
$ 19 B
Market Cap
-94.49
P/E
1. INTRINSIC VALUE
Balance Sheet
Natera, Inc.
| Current Assets | 1.38 B |
| Cash & Short-Term Investments | 968 M |
| Receivables | 314 M |
| Other Current Assets | 93.4 M |
| Non-Current Assets | 285 M |
| Long-Term Investments | 0 |
| PP&E | 248 M |
| Other Non-Current Assets | 36.7 M |
| Current Liabilities | 344 M |
| Accounts Payable | 34.9 M |
| Short-Term Debt | 90.5 M |
| Other Current Liabilities | 219 M |
| Non-Current Liabilities | 121 M |
| Long-Term Debt | 96.6 M |
| Other Non-Current Liabilities | 24.7 M |
EFFICIENCY
Earnings Waterfall
Natera, Inc.
| Revenue | 1.7 B |
| Cost Of Revenue | 674 M |
| Gross Profit | 1.02 B |
| Operating Expenses | 1.25 B |
| Operating Income | -222 M |
| Other Expenses | -31.9 M |
| Net Income | -190 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Natera, Inc.
| Net Income | -190 M |
| Depreciation & Amortization | 31 M |
| Capital Expenditures | -66.4 M |
| Stock-Based Compensation | 274 M |
| Change in Working Capital | 0 |
| Others | 20.7 M |
| Free Cash Flow | 69.2 M |
Wall Street Analysts Price Targets
Natera, Inc.
Wall Street analysts predict an average 1-year price target for NTRA of $154 , with forecasts ranging from
a
low of
$120 to a high of $195 .
NTRA Lowest Price Target
Wall Street Target
120 USD
-13.61%
NTRA Average Price Target
Wall Street Target
154 USD
11.05%
NTRA Highest Price Target
Wall Street Target
195 USD
40.39%
4. DIVIDEND
ANALYSIS
NTRA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Natera, Inc.
Sold
0-3 MONTHS
20.9 M USD 8
3-6 MONTHS
75.3 M USD 8
6-9 MONTHS
63.2 M USD 11
9-12 MONTHS
9.93 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~200 patients (>1,300 plasma samples) with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY.
businesswire.com
- 2 weeks ago
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay. Signatera in CRC surveillance Data on >.
businesswire.com
- 3 weeks ago
Nearly 16 % of Druckenmiller's Money Now Rides on This Stock
A high-growth gem is the largest holding in Stanley Druckenmiller's firm's fund.
247wallst.com
- 1 month ago
Natera Announces Medicare Coverage for Signatera™ Genome
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring, mirroring the pre-existing coverage for Signatera. The coverage determination was supported by r.
businesswire.com
- 1 month ago
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study analyzed the performance of Signatera Genome in a cohort of 392 patients (> 2,600 plasma samples) across five different tumor types (breast cancer, non-small cell lung cance.
businesswire.com
- 1 month ago
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analys.
businesswire.com
- 2 months ago
Natera: The Clues In Q1 Earnings
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signatera, projecting it could become a $5 billion annual product as both volumes and ASPs rise. Natera consistently outperforms its own conservative guidance, suggesting future earnings beats are likely, especially with unmodeled 'true-up' revenue.
seekingalpha.com
- 2 months ago
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
- 2 months ago
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
seekingalpha.com
- 2 months ago
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago.
zacks.com
- 2 months ago
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712.
businesswire.com
- 2 months ago
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection. Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor fraction (dd-cfDNA %, measuring dd-cfDNA as a fraction of total cfDNA) and donor quantity score (DQS, estimating the to.
businesswire.com
- 2 months ago
8. Profile
Summary
Natera, Inc. NTRA
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 19 B
Dividend Yield
0.00%
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Contact
13011 McCallen Pass Building A, Austin, CA, 78753
https://www.natera.com
IPO
Date
July 1, 2015
Employees
4424
Officers
Dr. Matthew Rabinowitz Ph.D.
Co-Founder & Executive Chairman
Mr. Jonathan Sheena M.Eng.
Co-Founder & Director
Mr. Eric A. Evans Ph.D.
Chief Scientific Officer
Mr. Michael B. Brophy M.B.A.
Chief Financial Officer
Ms. Olesya A. Anisimova CPA
Chief Accounting Officer
Mr. John Fesko
President & Chief Business Officer
Mr. Daniel Rabinowitz L.L.M.
Secretary & Chief Legal Officer
Mr. Solomon Moshkevich M.B.A.
President of Clinical Diagnostics
Mr. Rishi Kacker
Chief Technology Officer
Mr. Steven Leonard Chapman
Chief Executive Officer & Director